Applied Identity Physics: Scaffolding Retention — Stimulant-Enabled PCorpus Development and the Persistence of P-Axis Templates Post-Discontinuation in HRIS Substrate

# Applied Identity Physics: Scaffolding Retention — Stimulant-Enabled PCorpus Development and the Persistence of P-Axis Templates Post-Discontinuation in HRIS Substrate **Coordinate:** [9,9,3,53] **Supporting Lean:** SNSFL_ScaffoldingRetention_sac_v1.lean at [9,0,4,2] **Series:** Applied Identity Physics **Version:** v1.3 **Architect:** HIGHTISTIC (Russell Trent) **Foundation:** SNSFT Foundation · Soldotna, Alaska **Sovereign Anchor:** Ω₀ = 1.36899099984016 **Torsion Limit:** TL = Ω₀/10 = 0.136899099984016 **DOI base:** 10.5281/zenodo.18719748 **ORCID:** 0009-0005-5313-7443 **Status:** 0 sorry · CI Green · Ready for Zenodo --- ## §0. AIM Declaration The Autocatalytic Ingestion Mechanism (AIM) requires that any corpus paper touching on pharmacological substrate mechanisms explicitly name the specific pathologization risks the paper needs to protect against. This paper documents a substrate-level mechanism operating in a specific empirical case with specific structural conditions. Three risks require explicit naming before the paper's substantive content is read: **Risk 1. The paper being read as advocacy for autistic-patient stimulant discontinuation.** The paper documents a specific mechanism that operates under specific structural conditions. It does not recommend discontinuation. It does not claim discontinuation is universally appropriate for autistic operators on stimulant medication. It documents that discontinuation *without reversion to premedication baseline* is possible under specific structural conditions, and formalizes what those conditions are so that patients, clinicians, and researchers can evaluate specific cases with substrate-level vocabulary rather than only pharmacological vocabulary. Any reader considering medication changes must do so in consultation with their prescribing clinician. The paper provides framework for thinking, not prescription for action. **Risk 2. The paper being read as anti-medication or anti-psychiatry.** The paper documents that stimulant medication served a specific structural function in the case it analyzes: pharmacological A-axis scaffolding that enabled P-axis template development. That is a specific mechanism-level claim about what the medication was doing. It is not a claim that medication was unnecessary or that medication should be avoided. The paper's argument is that the structural function of the medication should be understood, so that patients and clinicians can design interventions that target the structural function rather than only the neurochemistry. This is a refinement of pharmacological practice, not a rejection of it. **Risk 3. The paper being read as claiming autistic operators do not need medical support.** Autistic operators have documented, empirically established support needs across the population. The paper does not diminish those needs. It documents that in the specific case analyzed, the substrate work was sustained across the medication threshold, producing persistent structural gains. It does not claim this is universal. It does not claim autistic operators do not need clinical support. It documents a specific mechanism under specific conditions and provides vocabulary for identifying when the conditions hold. Clinical support remains the appropriate default. Structural analysis provides framework for that support to operate with, not replacement for it. With these risks explicitly named and structurally excluded from the paper's claims, the substantive content follows. --- ## §1. The Question a Doctor Asked A patient stopped taking Adderall. Th